Thyroid and Endocrine Tumors

  • M. Eiber
  • F. Gärtner
  • K. Scheidhauer
  • M. Souvatzoglou


In thyroid cancer 18F-FDG is well established for detection of noniodine-avid disease in patients with elevated Tg levels. From a prognostic perspective it is known that patients with FDG-avid, high-volume disease (>125 mL) as assessed with CT and PET have markedly reduced survival. Thus FDG PET is a tool for assisting in the clinical decision making for either localized or systemic therapy other than the use of 131I in patients with negative iodine scans and elevated hTg and in patients with suspected local recurrence after thyroidectomy. One important prerequisite of using 18F-PET-CT for this patient is that when using it combined with a 131I-scan or when potentially a radio-iodine-therapy is planned no intravenous contrast should be administered for the diagnostic CT. Here PET-MR can offer the possibility to add a diagnostic morphological dataset to the PET-examination as Gd-based contrast media do not interfere with the use of a 131I-scan or therapy. Additionally PET-MR is expected to be a useful tool in surgical planning and radioactive iodine therapy decisions.


Thyroid Cancer Attenuation Correction Papillary Thyroid Cancer Medullary Thyroid Cancer 131I Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Macapinlac HA (2001) Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med 42(1):77–78PubMedGoogle Scholar
  2. 2.
    Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M (2001) Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42(1):71–76PubMedGoogle Scholar
  3. 3.
    Wang W, Macapinlac H, Larson SM, Yeh SDJ, Akhurst T, Finn RD et al (1999) [18F]-2-Fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. JCEM 84(7):2291–2302PubMedGoogle Scholar
  4. 4.
    Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M et al (1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26(12):1547–1552PubMedCrossRefGoogle Scholar
  5. 5.
    Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C et al (2008) Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid 18(2):103–111PubMedCrossRefGoogle Scholar
  6. 6.
    Mosci C, Iagaru A (2011) PET/CT imaging of thyroid cancer. Clin Nucl Med 36(12):e180–e185PubMedCrossRefGoogle Scholar
  7. 7.
    Abraham T, Schöder H (2011) Thyroid cancer—indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med 41(2):121–138PubMedCrossRefGoogle Scholar
  8. 8.
    Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M et al (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mo Imaging 34(10):1617–1626CrossRefGoogle Scholar
  9. 9.
    Schreiter NF, Nogami M, Steffen I, Pape U-F, Hamm B, Brenner W et al (2012) Evaluation of the potential of PET/MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol 22(2):458–467PubMedCrossRefGoogle Scholar
  10. 10.
    Ruf J, Lopez Hänninen E, Böhmig M, Koch I, Denecke T, Plotkin M et al (2006) Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology 6(6):512–519PubMedCrossRefGoogle Scholar
  11. 11.
    Tatsumi M, Isohashi K, Onishi H, Hori M, Kim T, Higuchi I et al (2011) 18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT. Int J Clin Oncol 16(4):408–415PubMedCrossRefGoogle Scholar
  12. 12.
    Kalra MK, Maher MM, Mueller PR, Saini S (2003) State-of-the-art imaging of pancreatic neoplasms. Br J Radiol 76(912):857–865PubMedCrossRefGoogle Scholar
  13. 13.
    Fidler JL, Johnson CD (2001) Imaging of neuroendocrine tumors of the pancreas. Int J Gastrointest Cancer 30(1–2):73–85PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • M. Eiber
    • 1
  • F. Gärtner
    • 2
  • K. Scheidhauer
    • 2
  • M. Souvatzoglou
    • 2
  1. 1.Department of Radiology, Klinikum Rechts der IsarTechnische Universität MünchenMunichGermany
  2. 2.Department of Nuclear MedicineTechnische Universität MünchenMunichGermany

Personalised recommendations